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Screening, high-throughput screening, and ultra-high-throughput screening are all really just points on a
spectrum that represent differing applications of the same process: the creation of biologically relevant
assays that are relevant, reproducible, reliable, and robust. Whether the discovery program is developing
a pharmaceutical, an academic probe, cosmetics, pesticides, or a toxicity monitoring assay, the develop-
ment of a screen focuses on generating a method that will reliably deliver reproducible results over a period
of weeks, months, or years and that will generate consistent results for every test along the way. This review
provides both historical perspective on how this unique scientific discipline evolved and commentary on the
current state of the art technologies and techniques.Screening has changed quite a bit since the heyday of the 1990s.
At that time, industrialization was the watchword andmost phar-
maceutical companies were planning pipelines with sufficient
capacity to screen libraries of hundreds of thousands of com-
pounds against hundreds of targets per year. Millions of dollars
were spent annually to build highly automated high-throughput
screening (HTS) facilities, and chemical libraries were expanded
proportionally. But HTS did not save the world or the pharma-
ceutical industry. But then again neither did combi-chem,
computational chemistry, genomics, outsourcing, nor any of
the other industry-changing ‘‘paradigm shifts’’ that launched
multiple companies and sometimes led to massive reorganiza-
tions in pharma. Of course, those of us who lived through that
time and have worked in drug discovery for a reasonable length
of time know that the process of finding new drugs is a long, slow
one and that a successful program involves bringing many
approaches to bear at once and teams of scientists from many
disciplines working together. Success depends on having the
right team and the right target and getting the right compound.
So there is always a certain amount of luck involved; screening
is all about combining science with luck.
Screening, as the name implies, is a sifting process to find the
few compounds in a large set that have a desired biological
activity. This has often been used (andmisused) interchangeably
with high-throughput screening. HTS is often defined by the rate,
quantity, or automation level of the testing, but in reality both
represent a spectrum across all these factors, and it is nearly
impossible to draw a clean dividing line where HTS begins.
The basic premise of screening is that biological assays can be
performed in a manner that is relevant, reproducible, reliable,
and robust, and,most importantly, the screenmust employ tech-
niques that ensure there is reasonable confidence that the re-
sults will be biologically relevant.
It is important to understand the difference between an
‘‘assay,’’ a ‘‘screen,’’ and ‘‘screening.’’ An assay describes the
analytical method that is used to measure a biological process.
It does not imply any understanding of the variability or repro-
ducibility of the technique, which is why we always insist on1162 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltseeing biological replicates in publications. A screen, on the
other hand, differs from an assay in the rigor used in developing
and characterizing the final method, such that the impact of all
the components and processes on the end readout are under-
stood. When applied properly, this involves a rigorous assay
development and validation process that results in a biological
method that can be applied to test compounds over a period
of weeks, months, or years and for which the results generated
at the outset will be comparable to every test along the way.
Once that process has been completed, the screen can be
executed at virtually any throughput with compatible automa-
tion. This is critical to any drug discovery effort because a reliable
biological readout is required to guide medicinal chemistry pro-
grams, to test compounds from virtual screens and docking, and
to confirm the activity of compounds that enter the development
pipeline.
The processes behind screening have evolved over the last
century. Arguably, the first notable success from a screening
campaign was the discovery of penicillin in the early twentieth
century (Fleming, 1929). Of course, this process took almost
75 years to yield a drug (Sneader, 1985), which is a bit longer
than is expected in today’s environment. Screening, in the
form of HTS, really came into its own in the late 1980s, in
response to a number of factors, probably the most important
of which was the shift from phenotypic to target-based drug dis-
covery. Earlier efforts measured changes in whole organisms,
usually major shifts, such as gross physiological parameters in
animals (blood pressure, etc.) or antimicrobial effects. The
need to find drugs with specific targets was combined with the
fact thatmost pharmaceutical companies had accumulated rela-
tively large compound collections that they wanted to leverage.
The logical next step was to test the existing compound libraries,
plus any new compounds that were available, against every
target with the hypothesis that this would lead to new drug leads.
In other words, begin running HTS.
The success of HTS has been debated extensively in the liter-
ature (Bleicher et al., 2003; Landers, 2004; Macarron et al., 2011;
Pereira and Williams, 2007) and will not be addressed here. Thed All rights reserved
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lel with other approaches, such as rational design, substrate or
ligandmodeling, fragment screening, and amyriad of other tech-
niques and usually serves as a starting point for medicinal chem-
istry optimization. Because these starting points then undergo
significant modification and a large time lag that may involve
multiple departments, it can be difficult to point directly to drugs
that resulted from screening efforts. For example, Macarron et al.
(2011) compiled a list of 12 drugs that resulted directly from HTS
efforts for which the time from screen to drug launch varied from
6 (Sitagliptin) to 19 years (Tolvaptan). In reality, the more you
know about a target, the less likely you are to undertake a screen,
making it almost a tool of desperation in de novo discovery.
Because we prosecute more novel targets today, the despera-
tion levels remain quite high, and HTS remains one of the very
powerful tools in the drug discovery tool box. And a rigorously
developed screen is critical to every drug discovery effort
whether or not HTS yielded the starting points.
One measure of the impact of screening is the uptake of
screening techniques outside the pharmaceutical industry.
HTS is now being applied in the discovery of biopharmaceuticals
(Wu and Doberstein, 2006), catalysts (Senkan, 1998), plant sci-
ence (Colbert et al., 2001), pesticide research (Ridley et al.,
1998; Tietjen et al., 2005), cosmetics, and toxicity (Tice et al.,
2013). There has also been a significant shift to move screening
(and drug discovery techniques in general) into academia (Austin
et al., 2004; Frye and Janzen, 2007; Frye, 2010; Mullard, 2013).
This has provided much broader access to screening for scien-
tists outside the pharmaceutical industry. The downside of this
fairly sudden increase in academic capacity has been a very
steep learning curve for academic scientists, but fortunately
the increase in academic interest in screening coincided with
significant downsizing in the pharmaceutical industry. So many
experienced drug discovery experts were brought into academic
programs, allowing academia to come up to speed without
repeating all of the mistakes that were made in industry. One
advantage the academic labs share is access to novel
biology—there is never a shortage of interesting targets. The
two largest problems still facing academic drug discovery labs
are unrealistic expectations on the part of the principle investi-
gator sponsoring the target and access to high-quality libraries.
Many very experienced researchers still enter a screening
campaign expecting to get a drug or a highly potent probe
(Frye, 2010) directly from the screen. Academic labs also strug-
gle to access high-quality chemical diversity. Because the tar-
gets are often novel and may even be a novel target class, this
can compound the failure rates. It is difficult to tell a respected
scientist that their target was simply one of the 20% (Paul
et al., 2010) that do not generate tractable hits and that a consid-
erable amount of time and (usually hard-won grant) money
yielded nothing.
Probably the biggest changes in screening have been driven
by two concepts that seem obvious and simple in retrospect.
First, the standardization of labware. Prior to the introduction,
in 1999, of the SBSMicroplate Standard (Astle, 1997), each com-
pany had used slightly different dimensions for microplates,
often to match their own readers, pipettors, or robotics. This
automation nightmare ended with the establishment of standard
outside dimensions and well spacing. Although there is still vari-Chemistry & Biology 2ation in well type and depth, the array spacing is constant be-
tween plates. This standardization has now expanded to types
of high-throughput labware, such as microtubes and vials for
storage. The other big change was driven by the increase in ac-
ademic and government labs running screens and the academic
need to publish. These led to the broad dissemination of a com-
mon set of tools and technologies to support screening. This is,
perhaps, best exemplified by two examples: the Pubchem data-
base (Wang et al., 2009) and the NIH Assay Guidance Manual
(Sittampalam et al., 2008). The former was created as part of
the NIH Molecular Libraries Roadmap Initiative (Austin et al.,
2004). It serves as a repository for data from discovery efforts
funded through that program in a publicly available database.
Similarly, the Assay Guidance Manual was created through a
public-private partnership between Eli Lilly and Company and
theNIH to share common assay development techniques. Public
dissemination of screening data and techniques has led to the
creation of a common set of tools and techniques and has largely
made the concept of proprietary techniques in screening an
obsolete concept in drug and probe discovery.
Compound Libraries and Library Management
Compound libraries and their management are a key aspect of
screening and remain an area of very high importance in most
companies (Chan and Hueso-Rodrı´guez, 2002; Holland-Crim-
min et al., 2011; Janzen and Popa-Burke, 2009; Macarron
et al., 2011; Warne and Pemberton, 2009; Yasgar et al., 2008).
Because of the expense of assembling a library and the impor-
tance to discovery efforts, these are seen as the ‘‘family jewels.’’
Most companies now recognize the importance of managing
their libraries carefully and have created centralized groups (or
facilities) to store and manage the compound library (Janzen
and Popa-Burke, 2009; Wigglesworth et al., 2012). In a multisite
environment, this may extend to satellite facilities that have more
limited stores to process local requests and submissions.
The average pharmaceutical library today exceeds one million
compounds and has been created by a deliberate effort to
expand diversity in the collection, while maintaining novelty
and patentability (Bakken et al., 2012; Drewry and Macarron,
2010; Jacoby et al., 2005; Kogej et al., 2013; Macarron et al.,
2011; Renner et al., 2011). In combination with this deliberate
expansion, chemical biology approaches have driven an in-
crease in the understanding of target families and led to the
design of focused libraries (Deng et al., 2006; Harris et al.,
2011; Orry et al., 2006). These libraries contain compounds
based on their homology or predicted binding affinity to key
conserved domains in a target class (Akritopoulou-Zanze and
Hajduk, 2009; Gray et al., 1998; Heilker et al., 2009; Karaman
et al., 2008; Rognan, 2007); for example, kinase libraries will
be created based on their predicted affinity for the ATP pocket,
the hinge region, and known allosteric sites, whereas G-protein-
coupled receptor (GPCR)-focused libraries will be based on
known ligands and allosteric sites. These libraries are also
much smaller than a diversity library, usually in the range of
5,000 to 25,000 members. Often, good lead series can be ob-
tained from screening a focused library without resorting to the
expense and time of scaling up and miniaturizing a screen.
This work can be completed in a very short amount of time in a
core lab and can often be done in a therapeutic area lab. Using1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1163
Figure 1. Modular Compound Management Systems
(A) Standardized storage vessels. Compounds are stored in standardized
barcoded vessels. From left,
1. dry compound storage vials for up to gram quantities,
2. automation-friendly vials for dissolution and transfer,
3. microtubes for storage in automate tubes stores. The carrier is bar-
coded, and each tube is also tracked with a 2D barcode, and
4. barcoded microplates, different formats may be used for storage
and assay.
(B) Modular storage units. Modular storage units can be arrayed and added
or removed as capacity needs change. These units can be isolated and used
as independent workstations or connected by a variety of automated com-
pilers that range from robotic arms to conveyer systems to pneumatic tubes.
Once a set of compounds is compiled, it is transferred to microplates that
can be stored for later use or transferred directly to automated screening
systems.
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focused strategies fail.
The shift to smaller libraries and alternate discovery strategies
has led to significant shifts in how compounds libraries are
stored and managed. In large companies, compound manage-
ment groups are faced with the need to manage over one million
samples in both powder form and solubilized in DMSO (Wiggles-
worth et al., 2012). Powder stores are always problematic (Wig-
glesworth et al., 2012). The amount stored can vary from a few
milligrams to several kilograms for each compound, and auto-
mated weighing systems have proven to be difficult, largely
because of the diversity of sample types (solid, liquid, oil, pow-
der, hygroscopic, flake, etc.). The most common solution for
this disparity is to create a set of samples that are stored in
standardized, barcoded, and automation-friendly vials. As com-1164 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltpounds are purchased or synthesized, these standardized vials
are used for storage to allow ease of storage and processing,
using automated equipment. Often, multiple samples will be
stored in a standard vial as well as in larger, nonstandard storage
vessels for larger quantities. These vials are then used in turn to
weigh small samples that will be used to make DMSO-solubi-
lized samples, again in standardized vials or into plates for stor-
age in the actual screening format (Janzen and Popa-Burke,
2009) (Figure 1A).
This, combined with advances in automation and dispensing
technologies, has also led to a shift in how these samples are
stored. The actual repository has changed from monolithic,
room-sized storage systems to the creation of smaller, more
modular systems, such as the comPOUND (TTP Labtech), Sam-
ple Store II (Brooks), Sample Vault (HiRes Bio), and the Active
Sample Manager (Hamilton), to name just a few. These systems
do not require the gymnasium-sized automation units or team of
engineers that typified storage systems at the end of the previ-
ous century. Instead, modular storage units hold significant,
but not overwhelming, numbers of compounds (10,000 to
200,000) in a self-contained unit that includes automation sys-
tems to pick and place compounds. For solubilized DMSO
libraries, the compounds will usually be stored in smaller aliquots
that can be placed in a 96-tube rack with the same dimensions
as a 96-well microplate (Figure 1A). For both powder and
liquid-phase systems, modular approaches allow the facility to
plan their capacity needs on a much shorter horizon. Investing
in a system with a 10-year lifetime and little room for expansion
requires that one plan their library expansion on a similar time-
scale. With a modular approach, one can simply add or subtract
storage units as capacity needs change (Figure 1B). Another
advantage of this approach is that the units do not have to be
connected into a fully automated system but can be operated
as standalone workstations, while still being integrated into a
very efficient workflow.
HTS is built on the same principles as in manufacturing in that
both use similar workflowmanagement techniques. The concept
of just in time (JIT) grew from manufacturing processes imple-
mented at Toyota (Ohno and Mito, 1988) and have evolved into
the broad concept of reducing inventory andwaste by producing
materials as needed. Limitations in the volumes that liquid-
handling robotics could dispense in array formats restricted
the creation of JIT plates to the use of pin tools (Cleveland and
Koutz, 2005) until the recent introduction of acoustic dispensing
technologies (Ellson et al., 2003). Although pin tools do allow
rapid transfer of semiprecise volumes, there are concerns
about accuracy and cross-contamination. Acoustic technolo-
gies allow noncontact dispensing of picoliter volumes, thereby
also reducing the DMSO concentration in assays. When inte-
grated with plate-handling systems, these systems can produce
single copies of an entire library in ‘‘ready-to-screen’’ assay
plates, thus enabling JIT production.
Screening Technologies
So the more things change, the more they stay the same.
Screening is now a commonly used technique in both academia
and industry and has evolved as sets of standardized tools and
techniques. Two of the biggest issues from a decade ago,
namely, automation and miniaturization, have largely becomed All rights reserved
Figure 2. Application of Screening Technologies to Cellular or
Biochemical Assays
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mation has becomemodular, creating systems that can be easily
expanded and modified, as well as allowing components to be
used in offline modes. The greatest advances in laboratory auto-
mation over the last decade have not been the introduction of
more complex robotics but have been simplification and
increased reliability. With graphical interfaces and hot swapping
docks that actually work, laboratory automation is no longer
restricted to core labs. Similarly, miniaturization is de rigueur,
and it is rare to find an application that cannot be miniaturized
to 1,536-well plates. I do not want to imply these technologies
have become static—far from it. But the advances in this area
are becoming evolutionary rather than revolutionary.
The pressure to develop new assay techniques was originally
driven by the need to increase throughput and miniaturize
assays. This led to a move away from traditional assay tech-
niques that required separations, washing, gels, or transfers to
homogenous assay technique (add and read). Because the as-
says that were being scaled up utilized radioactive readouts or
simple fluorescent intensity changes, most of these early assays
were adaptations of those techniques. As throughputs con-
tinued to increase, radioactive methodologies were restricted
to low-intensity emitters, such as 3H, and have now almost
completely disappeared from the HTS repertoire. In fact, many
screening labs do not even have radiation licenses. Sophisti-
cated techniques that allow high-throughput, homogeneous
screening assays exist for almost any target today. Many of
these developments were driven by the need to investigate
new aspects of biological signaling, while others offer opera-
tional advantages over existing techniques.
One common problem in the field of screening has been the
tendency to artificially compartmentalize: for example, ‘‘cell-
based screening versus biochemical screening’’ or ‘‘phenotypic
versus targeted screening.’’ To be successful, a screening lab
must be able to utilize multiple technologies and approaches de-
pending on the question being asked. As can be seen in Figure 2,
whether emerging or established, the technologies used in
screening tend to cross the cell versus biochemical line, and
the same is true of most other ‘‘versus’’ divisions. In fact, the
screener needs to have a complete toolbox because a drug or
probe discovery program will need to utilize multiple technolo-
gies and approaches to reach the eventual goal of a well-charac-
terized probe or a therapeutic molecule. A summary of those
techniques is listed below.Chemistry & Biology 2Scintillation proximity assay (SPA) (Cook, 1996) (PerkinElmer)
is the only radioactive technique that will be discussed here.
SPA is a homogenous technique that relies on a basic principle
of physics; low-energy b particles created by radioactive decay
will be quenched rapidly in aqueous substrates. SPA is most
commonly used with 3H (although it will work with 125I and 33P
as well) because b particles from 3H decay have a path length
of approximately 1.5 mm inwater. In normal scintillation, counting
these decays would be marked by photon emission near the
decay site. In SPA, the scintillant is embedded in a bead, so light
emission can only occur if the radioactivemolecule decayswithin
the quench distance of the bead. The bead is functionalized with
specific binding moieties designed to capture the biological pro-
cess of interest. For example, receptor binding can bemeasured
by capturing the receptor to be interrogated on the bead using an
antibody, glutathione S-transferase bead and biotin-tagged pro-
tein, or other capture technique and a ligand with known affinity
that is radioactively labeled. In equilibrium with no receptor only
a very small percentage of the ligand will be within the quenching
radius of the bead. On the other hand, if the ligand binds to the re-
ceptor, then it is brought into the detection zone and now can
stimulate thebead that emits light. In addition to receptor binding,
SPA has been used for a wide range of targets, including protein-
protein interactions,GPCRs, ion channels, andenzymatic assays
(including kinases and proteases). SPA assays are still used in
screening but are rarely used in high throughput because of
waste disposal and safety issues. Unfortunately, because the
addition of a fluorescent tag can significantly alter the binding
affinities of ligands, radioactivity often remains as the best option
to measure some interactions.
Direct fluorescence measurement is probably the simplest
technique to use in an assay. Unfortunately, it is also the tech-
nique with the highest rate of interference from compounds
and debris (Busch et al., 2013; Simeonov et al., 2008). Of course,
the interference from innate compound library fluorescence can
be ameliorated by using red-shifted dyes, but not completely.
Nevertheless, it is widely used in both cellular and biochemical
assays, particularly in academic labs in which cost and access
to complex plate readers may be limiting factors. Direct fluores-
cence is most commonly used today in assays in which a
quenching reaction can be measured. For example, a protease
assay can be constructed where a substrate peptide is labeled
on one end with a fluorescent dye and on the other end with a
quenching dye. When the peptide is cleaved, the quenching re-
action is broken and a fluorescent signal is produced (Johnston
et al., 2007; Jones et al., 1997). Another less common use is the
innate quenching of fluorescent tags (Nomura et al., 2011),
where environmental or protein folding changes are utilized to
measure binding or other changes of compounds. Direct fluores-
cence is also widely used in cellular imaging assays and in
measuring kinetic changes, but those are separate enough ap-
plications to warrant separate treatment (see HCS and FLIPR).
Fluorescence polarization (FP) (Bolger and Checovich, 1994;
Checovich et al., 1995; Jolley, 1996) is often used interchange-
ably with the term anisotropy. It takes advantage of the fact
that a fluorescent molecule stimulated using polarized light will
emit light in the same polarization plane. By using the dual
properties of fluorescent lifetime and rotation rate, one can
then discriminate among the sizes of molecules based on their1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1165
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binding of small molecules or peptides to proteins (Nikolovska-
Coleska et al., 2004; Parker et al., 2000), making it useful for
measuring receptor-ligand interactions, protein-protein binding,
where one member of the binding pair is much smaller than the
other, and peptide, RNA, or DNA binding assays. It can be used
to assay the cleavage of peptide fragments from a substrate by
proteases (Jolley, 1996) and can also be used for the quantifica-
tion of ligands or cofactors (Gaudet et al., 2003). FP is a quick
and easy technique to develop (Huang and Aulabaugh, 2009),
but it does require a specialized reader with the ability to read
parallel and perpendicular channels of emission. Perhaps the
biggest problem with FP is that of interference by fluorescent
compounds. If a test molecule is fluorescent and emits at the
same wavelength as the tag utilized in the assay or quenches
at that wavelength, it can produce false results (either positive
or negative). Mild fluorescence can be normalized by reading
background levels on each plate and subtracting those readings
from the final assay reading, but strongly fluorescent com-
pounds or compounds will saturate both channels and can still
interfere. As with direct fluorescence, there has been a major
shift to use FP labels that fluoresce in the red spectra to avoid
the major interfering range of small molecule compounds (Jad-
hav et al., 2010; Simeonov et al., 2008; Vedvik et al., 2004).
Fluorescence resonance energy transfer (FRET) relies on the
energy transfer between two fluorescent molecules using nonra-
diative dipole coupling (Clegg, 1995). Put more simply, a fluoro-
phore (donor) that emits at a second fluorophore’s (acceptor)
excitation wavelength and is within the dipole radius (usually
less than 10 nm) will not emit but will transfer that energy to
the acceptor molecule. The end result being that one can deter-
mine whether two dyes are in close proximity by exciting at the
donor wavelength and reading at the acceptor wavelength.
This technique has been used in HTS (Gonza´lez and Tsien,
1997) in much the same way as SPA to measure molecular inter-
actions, such as protein-ligand pairs. It offers the advantage of
being nonradioactive and can be read as a ratiometric readout
(donor emission/acceptor emission) to increase signal window
and decrease interference but still can suffer from fluorescent
interference from compounds and from minor debris in wells
(Busch et al., 2013). Although FRET is used in biochemical
assays, it has never seen wide acceptance because of interfer-
ence issues, the tight tolerances for interaction distance, and
the need to carefully match FRET pairs for each assay. These
are not insurmountable problems, but there are more facile tech-
nologies available (see time-resolved fluorescence, SPA, and
AlphaScreen).
However, FRET has become widely used for cellular assays. It
has been used as a transcription reporter (Gonza´lez and Negu-
lescu, 1998; Zlokarnik, 2000), most commonly using a non-
mammalian enzymatic system, such as insect b-lactamase
(Zlokarnik, 2000) and a FRET pair substrate (Life Technologies).
As the available wavelengths of fluorescent proteins have
expanded (Heim et al., 1994; Heim and Tsien, 1996), FRET has
also been widely used to monitor intracellular protein interac-
tions (Mitra et al., 1996; Piljic and Schultz, 2009). Because one
of the proteins can be an antibody (Snapp and Hegde, 2006),
this allows the monitoring of localization as well. FRET is often
used in high-content screening (HCS) approaches but can also1166 Chemistry & Biology 21, September 18, 2014 ª2014 Elsevier Ltbe used to monitor cell populations in multiwell plates (Tian
et al., 2007).
Time-resolved fluorescence (TRF, HTRF, and TiRF) is a variant
of FRET that utilizes a long-wavelength donor, such as a euro-
pium or terbium chelate (Bazin et al., 2001; Du and Havel,
2012). The basic theory behind TRF is that most fluorescent
emissions are short lived (nsec), so the long decay time for the
donor molecule (msec) will allow interfering compound fluores-
cence to decay prior to measurement of the primary signal.
This does work well and reduces the compound interference,
but not completely (Imbert et al., 2007). Time-resolved technolo-
gies can be constructed as homogeneous assays (Bazin et al.,
2001) (PerkinElmer: Lance, cisBIO, HTRF). TRF is widely used
in screening and is compatible with very high throughputs. It
has been used for direct binding assays but can also be used
for a wide range of targets by incorporating secondary binding
agents, such as antibodies. This has allowed TRF to be used
for functional GPCR assays by measuring G-protein-mediated
effects, such as cyclic AMP levels, and for kinases using phos-
phorylation-specific antibodies (Degorce et al., 2009).
AlphaScreen is a technology marketed by PerkinElmer that re-
lies on a chemiluminescent bead pairing (Beaudet et al., 2001;
Wigle et al. 2010a). In AlphaScreen, as in FRET, TRF, and SPA,
molecular interactions between two moieties are measured by
proximity. One interacting element is coupled to a donor bead,
and the other is coupled to an acceptor. When the donor is
stimulated with at 680 nm, it converts ambient oxygen to singlet
oxygen. Singlet oxygen has a very short half-life in an aqueous
environment and can travel approximately 200 nm before decay-
ing. If the acceptor beads are within this radius, then the singlet
oxygen initiates a chemiluminescent reaction in the acceptor
bead, which emits light in the 520–620 nm range. A number of
bead functionalities, such as streptavidin, nickel, protein-A
glutathione, or unconjugated, are available to allow the attach-
ment of almost any protein. AlphaScreen is very resistant to
direct fluorescent interference because of the wavelengths
involved, but compounds can still interfere by directly quenching
the signal. Reactive compounds or chelators can also interfere
by quenching or reacting with the singlet oxygen. AlphaScreen
has become widely used in screening and is very compatible
with high throughput and miniaturization. Similar to TRF and
SPA, it has been used for a very wide range of assays in which
a binding event can be used to quantify a reaction. AlphaScreen
has also been adapted to replace ELISA in a no-wash format
(AlphaLISA) (Bielefeld-Sevigny, 2009). The larger distance be-
tween bead pairs offers an advantage for measuring large pro-
tein binding events.
High-content screening (HCS) grew from the observation that
many biological interactions could be observed microscopically
but could not bemeasured in awhole-well assay. Changes, such
as translocation, receptor internalization, intracellular trafficking,
neurite outgrowth, and toxicity, can be monitored using high
power or confocal microscopes, but the changes associated
with these processes involved localization changes rather than
total fluorescent signal changes (Giuliano et al., 2003; Taylor
and Giuliano, 2005; Zock, 2009). To serve this need, automated
microscopes and associated image analysis programs were
created. HCS has grown to be a widely accepted technology
in screening, and the commercially available instruments fromd All rights reserved
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(not a complete list) now have throughputs that allow their use
in HTS (Gabriel, 2011; Jones et al., 2012). HCS allows the inter-
rogation of complex biological questions in addition to simulta-
neous assessment of toxicity and virtually no interference from
intrinsic compound properties. However, assay development
for HSC is a complex process and still requires specific ex-
pertise, and throughputs are not on par with many other HTS
techniques.
The fluorescent-imaging plate reader (FLIPR) has become
almost ubiquitous in screening. The FLIPRwas a first-in-class in-
strument that utilized charge-coupled device imaging of a whole
plate to capture fluorescent readouts (Schroeder and Neagle,
1996). It was first introduced in 1996 and enabled the functional
screening of GPCRs. As such, it deserves its own treatment
here. The FLIPR (Molecular Devices) uses integrated, multitip
liquid handling combined with rapid-plate imaging to enable
the real-time capture of whole-well fluorescent levels in cellular
assays. The FLIPR is primarily used tomeasure calcium changes
in cells. This is accomplished using dyes that demonstrate
increased fluorescence intensity on binding calcium. A common
example is the Fluo-4 dye (Gee et al., 2000), which is usually
used with acetoxymethyl (AM) ester conjugations, for which
cleavage by proteases in the intracellular environment are
required to activate the compound. Cells are preloaded with
dye and then exposed to compounds using the internal pipette,
and increases in fluorescence (and inferred calcium) are
measured over time. The FLIPR has been broadly used for
GPCR research but has also been applied for ion channels and
other uses. Later incarnations of the FLIPR technology have
included no-wash dyes and FLIPR automation-friendly FLIPR
units (Molecular Devices). Of course, as with any technology,
FLIPR is no longer the only way to assay calcium flux, but no
other technology has captured the market in the same way.
Protein fragment complementation assays (PCA) is another
cellular technique that has been widely used in screening. The
basic concept of a fragmentation assay is that two halves of a
protein with either fluorescent or enzymatic activity are cloned
onto two different proteins and will become active when those
protein interact (Remy and Michnick, 2007). This has been
used in mapping protein-protein interaction networks (Wehrman
et al., 2002) but has also been applied in screening by conju-
gating enzyme fragments to measure b-arrestin trafficking as a
surrogate for GPCR activation (Eglen, 2002). This has become
more important as interest in biased receptor signaling has
grown (Allen et al., 2011; Violin and Lefkowitz, 2007).
Microfluidics is a technology with immense promise. But
microfluidics has also promised to change screening and create
a complete lab on a chip for decades (Sackmann et al., 2014;
Salimi-Moosavi et al., 1998; Woolley et al., 1998). It still has great
promise but so far has not had great success in penetrating the
screening market. Microfluidic systems are commercially avail-
able, but the most common use is for analytical applications
(e.g., Agilent 2100 Bioanalyzer, BioRad Experion System, and
PerkinElmer Labchip), DNA Sample Prep (Illumina NeoPrep)
and Safety Analysis (Acea Biosciences). The PerkinElmer EZ
Reader is a Microfluidic Capillary Electrophoresis system that
has been widely used in screening (Bernasconi et al., 2007;
Blackwell et al., 2009; Johnson et al., 2002; Kopf-Sill, 2000; LiuChemistry & Biology 2et al., 2008; Sackmann et al., 2014; Wigle et al., 2010b). It
offers advantages in terms of precision and accuracy and low
false-positive and false-negative rates, as well as very low com-
pound-interference rates. The Acea technology is a flow cytom-
etry technology that will be discussed in that section (below).
Microfluidics continues to be heavily used in academia, where
custom chips can be created for each application but is
hampered in screening applications because of the need for a
facile ‘‘chip-to-world’’ interface that will allow access to the
millions of compounds in a chemical library.
Flow cytometry (flow) is an example of a technique that is
extremely widely used in biological assays but has not been
widely used in screening because of hardware limitations. Virtu-
ally every university and pharmaceutical company has a flow
core lab, and many labs have their own flow instruments. The
flow cytometry market for new instruments is estimated to
be >$1.5 billion in 2015 (Research, 2011). The main limitations
to using flow in screening have been the throughput and the
complexity of the instrumentation. Flow has been used in HTS
as early as 2004, as part of the NIHMolecular Libraries Roadmap
Initiative (Edwards et al., 2004), but only recently have instrument
manufacturers begun offering systems that are truly screening
compatible with screening (Becton Dickinson, Acea, Intellicyte,
and Miltenyi Biotec). Flow assays in screening offer many of
the same advantages of HCS, such asmultiparametric measure-
ment and assessment of complex biological questions in cell-
based assays (Becker et al., 2004; Black et al., 2011; Krutzik
and Nolan, 2006). It has also been used for bead-based assays
(Roman et al., 2007; Sklar et al., 2007), allowing biochemical
assay applications.
Label-free technologies are a broad class of screening tech-
niques that allow the analysis of changes in a biological system
without the requirement that any of the included components
be labeled. These systems can be used for both biochemical
and cellular assays. In the former, one of the molecules will usu-
ally have to be tagged with an attachment label and will be
affixed to a surface on which biophysical measurements are
used to determine the binding of a second molecule. For the
latter, cells are plated onto a specialized detection surface,
and internal changes are monitored. There are many technolo-
gies that are used in label-free applications that have been
reviewed elsewhere (Cooper, 2006; Du et al., 2012). For
biochemical interactions, they all share the common advantage
of measuring native protein interactions directly. The problem of
nonspecific compound interaction is quite different for label-free
technologies. Rather than interference with the detecting tech-
nology, some compound simply binds promiscuously and will
interfere. In fact, these compounds can bind directly to the
detection surface and require regeneration of the system. But
this is a rare event in compound libraries that have been filtered
for drug likeness.
Conclusions
The basic techniques listed above have become the screener’s
toolbox and can cover most of the assays in discovery today.
But all offer advantages and disadvantages (Figure 3). As our
understanding of the biological processes underlying disease
advances, there is a continual need to develop new techniques
and assays to interrogate these increasingly complex systems.1, September 18, 2014 ª2014 Elsevier Ltd All rights reserved 1167
Figure 3. Relative Complexity and Degree of Compound
Interference for Screening Technologies
Complexity is based on the difficulty of assay development, instrumentation
required, and operational issues. Compound interference represents how
prone that technology is to interference from small molecule compounds in a
typical screening library.
Chemistry & Biology
ReviewThe academic push to develop new chemical probes also
continually pushes us into new areas of biology. This leads to
the continual development of new screening technologies. You
can be sure that the list of technologies used in screening will
continue to evolve to meet the needs of discovery.
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